Company Overview and News
KUALA LUMPUR (Sept 18): The retention of office by Multi Sports Holdings Ltd executive directors Lin Huozhi and Lin Liying, whose whereabouts cannot be ascertained, is prejudicial to public interest, said Securities Commission Malaysia (SC).
5150 BSMAF 1818
KUALA LUMPUR (July 11): Multi Sports Holdings Ltd slumped 25% early today after it clarified that the reprimand it received from the Securities Commission Malaysia (SC) for knowingly furnishing financial statements that were false or misleading to Bursa Malaysia was related to five quarterly earnings.
5150 BSMAF 1818
KUALA LUMPUR: Multi Sports Holdings Ltd has clarified that the reprimand it received from the Securities Commission Malaysia (SC) for knowingly furnishing financial statements that were false or misleading to Bursa Malaysia was related to earnings for five quarters.
5150 BSMAF 1818
KUALA LUMPUR (July 11): The FBM KLCI looks poised to extend its gains cautiously today in line with the overnight advance at most global markets, as trade war worries ebbed somewhat.
TGLVY 5150 5219 7113 MYPRY TPGVF 5014
KUALA LUMPUR (July 10): Based on corporate announcements and news flow today, stocks that will draw some attention on Wednesday (July 11) may include: Pestech, Multi Sports, MAHB, Kian Joo, Box-Pak and Top Glove.
3522 TGLVY 5150 5219 7113 MYPRY TPGVF BSMAF 5014 1818
KUALA LUMPUR (July 4): The FBM KLCI is expected to trend lower today in line with the weaker overnight close at most global markets as mounting concerns over the a U.S.-China trade spat keeps investors on tenterhooks.
6912 4995 4863 5225 5150 7206 0082 MYTEF Q0F IHHHF 3484
KUALA LUMPUR (June 19): The FBM KLCI was down 0.42% at mid-morning today, in line with the pullback at most regional markets as the tariff tit-for-tat between the US and China intensified.
HLFBF APEXF 7090 5150 4065 1082 5681 BATS 4162 5014 7123 3026 3867 1996 0026 MYPRY 3719
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...